In fact, because of the low plasma level of HSA-heme in healthy subjects (1.5×10−6 M), the heme-based catalytic properties of HSA appear to be relevant, especially in patients affected with hematologic diseases showing high intravascular hemolysis and high HSA-heme plasmatic levels (reaching 5×10−5 M).25,52 The heme-based catalytic properties of HSA are modulated allosterically by drugs, and, according to linked functions,53 the oxidation state and the axial coordination of the heme-Fe atom affect drug recognition.2 Here, ALB is linked to hematologic disorder.